Prognostic value of different sarcopenia assessment methods for mortality in patients with liver cirrhosis: a systematic review and meta-ana

Sarcopenia is a condition characterized by the loss of skeletal muscle mass and strength, which is common among patients with liver cirrhosis. Studies have shown that sarcopenia is closely associated with poor prognosis in these patients. However, the value of different methods for assessing sarcopenia in predicting mortality risk in patients with cirrhosis remains controversial. This systematic review and meta-analysis aims to systematically evaluate the predictive ability of different methods for measuring sarcopenia regarding mortality risk in patients with cirrhosis.

A total of 15 studies were included in this analysis, which evaluated the association between sarcopenia and the risk of mortality in patients with cirrhosis. The primary outcome measures were the hazard ratio (HR) and its 95% confidence interval. A meta-analysis was performed using a random-effects model, and subgroup analyses were conducted based on different assessment methods, including computed tomography (CT) imaging, handgrip strength (HGS), ultrasound (US), and dual-energy X-ray absorptiometry (DXA).

The results of this analysis showed that sarcopenia significantly increased the risk of mortality in patients with cirrhosis. In the CT assessment group, the overall pooled hazard ratio was 2.06 (95% CI: 1.65–2.57), indicating a significant association between CT-derived measurements and mortality risk. Subgroup analysis showed that the Skeletal Muscle Index (SMI) group had an HR of 1.88 (95% CI: 1.50–2.36), while the Psoas Muscle Index/Psoas Muscle Thickness/Transverse Psoas Muscle Thickness (PMI/PMT/TPMT) group had an HR of 3.19 (95% CI: 1.62–6.28). The Handgrip Strength (HGS) group had an HR of 2.21 (95% CI: 1.61–3.05), suggesting a significant association between reduced handgrip strength and mortality risk.

The results of this analysis also showed that the Dual-Energy X-ray Absorptiometry (DXA) group had an HR of 2.38 (95% CI: 1.47–3.84), indicating an increased mortality risk associated with reduced DXA-derived muscle mass. However, the strength and consistency of evidence varied across different assessment methods.

In conclusion, this systematic review and meta-analysis found that sarcopenia is associated with increased mortality risk in patients with cirrhosis. Among currently available assessment approaches, CT-derived measurements, particularly SMI, have the most consistent evidence base for mortality prediction. However, further large-scale prospective studies are required to validate the prognostic value of alternative assessment approaches. Future studies should establish standardized criteria for assessing sarcopenia to improve the accuracy of prognostic evaluations in patients with cirrhosis.

This systematic review and meta-analysis highlights the importance of accurately assessing sarcopenia in patients with liver cirrhosis. Laboratory peptides, such as those used in research settings, may be useful in evaluating muscle mass and strength in these patients. However, it is essential to note that this analysis was conducted for research purposes only and should not be used for clinical decision-making.

Due to the limitations of this analysis, including the limited number of studies evaluating certain assessment methods, further research is necessary to establish the prognostic value of alternative assessment approaches. Researchers should consult with experts in the field and follow established guidelines when conducting studies involving patients with liver cirrhosis.

In summary, sarcopenia is a significant predictor of mortality risk in patients with liver cirrhosis. Laboratory peptides may be useful in evaluating muscle mass and strength in these patients, but further research is necessary to establish their prognostic value. Researchers should prioritize the development of standardized criteria for assessing sarcopenia to improve the accuracy of prognostic evaluations in patients with cirrhosis.

For researchers using laboratory peptides, it is essential to note that this analysis was conducted for research purposes only and should not be used for clinical decision-making. The results of this analysis should not be applied to patient care without further validation and verification.